Loading
Lobular carcinoma in situ is not an invasive breast cancer but a marker that a woman is at higher risk of one: abnormal cells fill the milk-producing lobules without spreading. About one in five women develop breast cancer within ten years, in either breast and of any type; preventive tamoxifen cuts that to about one in fourteen, and the pleomorphic form is excised like ductal carcinoma in situ. Below, week by week, is what OnCo's record of Lobular carcinoma in situ (LCIS) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Surveillance and chemoprevention (tamoxifen or an aromatase inhibitor); TAM-01 tested low-dose tamoxifen in intraepithelial neoplasia.
Excision to clear margins because of the upgrade rate to invasive cancer or ductal carcinoma in situ.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
Every term links to the glossary.